In lenvatinib-resistant hepatocellular carcinoma, lactylation of IGF2BP3 at K76 promotes the generation of S-adenosylmethionine and induces RNA m6A modification, leading to drug resistance (Lu et al., 2024). This evidence concerns the gene IGF2BP3 and hepatocellular carcinoma.